GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (ASX:BLT) » Definitions » Net Interest Income

Benitec Biopharma (ASX:BLT) Net Interest Income : A$-0.04 Mil (TTM As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Benitec Biopharma Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Benitec Biopharma's net interest income for the three months ended in Mar. 2024 was A$-0.01 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2024 was A$-0.04 Mil.


Benitec Biopharma Net Interest Income Historical Data

The historical data trend for Benitec Biopharma's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Net Interest Income Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.09 -0.01 -0.05 -0.05

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Benitec Biopharma Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Benitec Biopharma Net Interest Income Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (ASX:BLT) Business Description

Traded in Other Exchanges
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Benitec Biopharma (ASX:BLT) Headlines

From GuruFocus

Olstein Strategic Opportunities Fund 2014 Investor Letter

By Canadian Value Canadian Value 04-01-2015

Blount International Inc. (BLT) CEO International Inc Blount buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-01-2009

Jean-Marie Eveillard Sells More Blount International

By Holly LaFon Holly LaFon 10-09-2012

Blount International Inc. (BLT) CEO Joshua L Collins buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 06-17-2010

John Rogers Exits Blount International in 1st Quarter

By David Goodloe David Goodloe 06-12-2016

John Rogers Trims Stake in Blount International

By Kyle Ferguson Kyle Ferguson 04-18-2016

Bill Nygren's Oakmark Comments on Blount International

By Holly LaFon Holly LaFon 07-10-2012